- Email: [email protected]
Pneumocystis Jirovecii Pneumonia (Pjp) in Non-Hiv Infected Patients with Solid Tumor
Annals of Oncology 25 (Supplement 5): v44–v74, 2014 doi:10.1093/annonc/mdu435.34
Oral Session (Oral presentations categorized by each organ) O1
16
1
Takafumi Koyama, Yuki Kasahara, Yasuyuki Shigematsu, Yoriko Hasegawa, Takao Fujisawa, Ayako Hiramatsu, Kotaro Matsumoto, Yukinori Ozaki, Ryuichi Sada, Yu Oyama Department of Medical Oncology, Kameda Medical Center
abstracts
Backgroud: There is growing a number of Pneumocystis jirovecii pneumonia (PJP) in Non-HIV-infected population. These patients typically present with severe disease. The purpose of our study was to describe the population involved, and to assess clinical, biological, and mortality date in solid tumor patients.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v51/2240259 by guest on 26 October 2019
PNEUMOCYSTIS JIROVECII PNEUMONIA (PJP) IN NON-HIV INFECTED PATIENTS WITH SOLID TUMOR
Methods: The medical charts of all patients with malignancy in our department of Kameda Medical Center between 2008 and 2013 were retrospectively reviewed. The clinical and laboratory data with a proven first episode of PJP diagnosed were abstracted. The diagnosis was made by microscopy with staining or polymerase chain reaction (PCR) of induced sputum or bronchoalveolar lavage (BAL) fluid. Result: Of the 2344 patients with malignancy, six were included in this study, median age 66 (49-80). Underlying cancers were lung cancer (2), gastric cancer (1), rectal cancer (1), prostate cancer (1) and thymic cancer (1). Five patients complained of dyspnea, and one complained of fever. Median duration of disease was 9.5 months. Performance Status (PS) was as follow: four patients were PS-1, one PS-3, and one PS-4. Median lymphocyte count was 1108/mm(3). Beta-D-glucan levels were higher than the normal range in 5 patients (median level:28pg/ml). Within 30 days before the diagnosis of PJP, 80% patients were given steroids at median cumulative 30-day dose of 38 mg dexamethasone. No patient had a PCP prophylaxis. One patient died of PJP (17%). The radiographic findings of all patients were diffuse, bilateral, interstitial infiltrates. Conclusion: The incidence of PJP in solid tumor patients (0.26%) is higher than we have expected. The mortality rate was high (17%). This study suggested the possibility of PJP should be considered when we treat malignancy patients whose complains are dyspnea.
Oral Session (Oral presentations categorized by each organ) O1
16
1
Takafumi Koyama, Yuki Kasahara, Yasuyuki Shigematsu, Yoriko Hasegawa, Takao Fujisawa, Ayako Hiramatsu, Kotaro Matsumoto, Yukinori Ozaki, Ryuichi Sada, Yu Oyama Department of Medical Oncology, Kameda Medical Center
abstracts
Backgroud: There is growing a number of Pneumocystis jirovecii pneumonia (PJP) in Non-HIV-infected population. These patients typically present with severe disease. The purpose of our study was to describe the population involved, and to assess clinical, biological, and mortality date in solid tumor patients.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v51/2240259 by guest on 26 October 2019
PNEUMOCYSTIS JIROVECII PNEUMONIA (PJP) IN NON-HIV INFECTED PATIENTS WITH SOLID TUMOR
Methods: The medical charts of all patients with malignancy in our department of Kameda Medical Center between 2008 and 2013 were retrospectively reviewed. The clinical and laboratory data with a proven first episode of PJP diagnosed were abstracted. The diagnosis was made by microscopy with staining or polymerase chain reaction (PCR) of induced sputum or bronchoalveolar lavage (BAL) fluid. Result: Of the 2344 patients with malignancy, six were included in this study, median age 66 (49-80). Underlying cancers were lung cancer (2), gastric cancer (1), rectal cancer (1), prostate cancer (1) and thymic cancer (1). Five patients complained of dyspnea, and one complained of fever. Median duration of disease was 9.5 months. Performance Status (PS) was as follow: four patients were PS-1, one PS-3, and one PS-4. Median lymphocyte count was 1108/mm(3). Beta-D-glucan levels were higher than the normal range in 5 patients (median level:28pg/ml). Within 30 days before the diagnosis of PJP, 80% patients were given steroids at median cumulative 30-day dose of 38 mg dexamethasone. No patient had a PCP prophylaxis. One patient died of PJP (17%). The radiographic findings of all patients were diffuse, bilateral, interstitial infiltrates. Conclusion: The incidence of PJP in solid tumor patients (0.26%) is higher than we have expected. The mortality rate was high (17%). This study suggested the possibility of PJP should be considered when we treat malignancy patients whose complains are dyspnea.